Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-025"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-025"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0262
lpv:speaker	lp:Ria Oomen-ruijten2
lpv:spokenAs	member; EPP-ED (1999-07-20--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3 substitute; EMPL (2002-01-17--2004-07-19)3 substitute; Committee on Women's Rights and Equal Opportunities (2002-01-17--2004-07-19)3 substitute; Temporary committee on foot and mouth disease (2002-01-17--2002-12-17)3 unknown; Christen Democratisch Appèl (1999-07-20--2004-07-19)3 vice-chair; Delegation for relations with South Africa (2002-02-07--2004-07-19)3
lpv:translated text	"Mr President, the problem of the great discrepancies in medicines policy in our Member States cannot be solved today. We are, however, taking a step in the right direction as far as greater harmonisation in registration is concerned and also with regard to the conditions for placing medicines, particularly generic medicines, on the market. Admittance to Member State markets, however, remains at the discretion of the individual Member States. One of today's important areas of discussion is the relationship between the original medicine and the generic product that is introduced onto the market once the patent and data protection have lapsed. A fragile compromise has been tabled, in respect of which I have tabled a better worded amendment. I would ask my fellow MEPs for their support, but I do endorse the compromise. In fact, I should also like to take this opportunity to issue a warning that speeding up the launch of a generic product will not automatically lead to lower costs. In the Netherlands, I have noticed that the price of a generic product there is higher than the price of the original medicine in a large number of Member States. I should also like to comment on pricing policy. Although we are once again bringing transparency to your attention, it is frustrating – and I am also addressing this comment to the rapporteurs of 1989 – that the directive on transparency is not being fleshed out. There are large discrepancies, and we will not solve them today. It is too ridiculous for words that medicines from the Netherlands, where the price paid by consumers for generic medicines is so high, are exported to other Member States in parallel. We should put a stop to this. Finally, I am not in favour of advertising. I am in favour of making self-regulating information accessible on the web. Whether this information originates from national agencies or the industry itself is irrelevant, as long as it is self-regulating. In my view, articulate consumers should not have to resort to websites in America but should also be able to access this information in Europe. I should ask you to carefully reconsider my amendments on this score."@en1
lpv:unclassifiedMetadata	"(Applause)"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph